Airway Therapeutics, LLC

13 articles with Airway Therapeutics, LLC

• Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Study of Zelpultide Alfa (AT-100) in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

  10/3/2022

  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced the first patient dosed in Spain in its ongoing Phase 1b Trial of zelpultide alfa (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).

• Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

  3/31/2022

  Airway Therapeutics, Inc. announced dosing of the first patient on March 28, 2022 in the Phase 1b randomized trial of AT-100 for preventative use in very preterm infants at risk for bronchopulmonary dysplasia.

• Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients

  8/26/2021

  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients.

• Airway Therapeutics Announces FDA Acceptance of IND for AT-100's Second Indication in Severe COVID-19 Patients

  4/12/2021

  Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced the U.S. Food and Drug Administration has accepted its Investigational New Drug application to develop AT-100 as a treatment for COVID-19.

• Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

  3/26/2021

  Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants

• Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus

  5/20/2020

   Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO s

• 

  Biopharma Update on the Novel Coronavirus: May 20

  5/20/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.

• Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus

  3/11/2020

  Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced a filing with the Respiratory Diseases Branch of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), to evaluate AT-100 (rhSP-D) as a therapeutic for the novel coronavirus (COVID-19).

• Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases

  1/8/2020

  Initiating bronchopulmonary dysplasia (BPD) clinical trial in very preterm infants in 2020 with orphan drug designation

• Airway Therapeutics Obtains License On Glycotope Cell Line

  9/11/2017

• Cincinnati's Airway Therapeutics Bags $6.3 Million

  3/7/2017

• Airway Therapeutics, LLC Closes $6.3M In Finance Round

  3/7/2017

• Airway Therapeutics, LLC Raises $4.6 Million In Series A Funding

  9/10/2014